Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Camp4 Therapeutics CorpCAMP · Entity 1161 | Director | August 03, 2026 | August 05, 2026 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Director | June 20, 2024 | June 21, 2024 |
| Syros Pharmaceuticals, Inc.SYRS · Entity 85437 | Director | September 16, 2024 | September 18, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Camp4 Therapeutics Corp
Report date August 03, 2026 · Filed August 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 186,388 |
Reported balance
After 2026-08-03 transaction · row 1
1 source rowRow 1 · 2026-08-03 · Purchase · Acquired 16,378 · Balance 186,388 F1: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share.
Omega Therapeutics, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2034-06-19 | Direct | 25,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 25,000 · Balance 25,000 F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
Syros Pharmaceuticals, Inc.
Report date September 16, 2024 · Filed September 18, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 10,667 |
Reported balance
After 2024-09-16 transaction · row 1
1 source rowRow 1 · 2024-09-16 · Exercise / conversion · Acquired 2,667 · Balance 10,667 F1: Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 2,667 |
Reported balance
After 2024-09-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-09-16 · Exercise / conversion · Disposed 2,667 · Balance 2,667 F2: Each RSU represents the contingent right to receive one share of the issuer's common stock. F3: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award
F2: Each RSU represents the contingent right to receive one share of the issuer's common stock.
F3: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 5, 2026 21:09 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 16,378 | $1.65 | $27,023.70 |
DisclosureSEC source: 0001628280-26-053513 · wk-form4_1785964164.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,388 F1 · price: On August 3, 2026, the reporting person acquired shares in the second closing of a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, as amended on August 3, 2026, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:16 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $4.34 | $0.00 |
DisclosureSEC source: 0001628280-26-042862 · wk-form4_1781295368.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-09 F1 · derivative.exercise_date: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date. Read SEC document |
| September 11, 2025 Filed Sep 11, 2025 20:22 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | PurchaseCommon Stock | 15,151 | $1.65 | $24,999.15 |
DisclosureSEC source: 0001490283-25-000003 · wk-form4_1757622149.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,010 F1 · price: On September 11, 2025, the reporting person acquired shares in a private placement by the Issuer pursuant to the terms of a Securities Purchase Agreement, dated as of September 9, 2025, by and among the Issuer and certain institutional investors and certain directors, employees, and consultants, at a purchase price of $1.65 per share. Read SEC document |
| June 25, 2025 Filed Jun 27, 2025 20:03 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001736730-25-000060 · wk-form4_1751054585.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 9,000 shares Expires 2035-06-24 F1 · derivative.exercise_date: The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the issuer's board of directors through the applicable vesting date. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 21:46 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionSeries A Prime Preferred Stock · Derivative | 100,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-108700 · tm2426125-2_4seq1.xml · derivative · entry 2 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,917 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. F1 · derivative.exercise_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. F1 · derivative.expiration_date: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. Read SEC document |
| October 15, 2024 Filed Oct 15, 2024 21:46 UTC | Camp4 Therapeutics Corp CAMP · Entity 1161 | ConversionCommon Stock | 8,917 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-108700 · tm2426125-2_4seq1.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. F1 · price: On October 15, 2024, the shares of Series A Prime Convertible Preferred Stock automatically converted into shares of Common Stock on a 11.2158-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:00 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionRestricted Stock Units · Derivative | 2,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-107862 · ownership.xml · derivative · entry 2 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,667 Underlying: Common Stock · 2,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents the contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023. F3 · derivative.expiration_date: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023. Read SEC document |
| September 16, 2024 Filed Sep 18, 2024 21:00 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 2,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-107862 · ownership.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit ("RSU") award Read SEC document |
| June 28, 2024 Filed Jul 2, 2024 20:15 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 34,837 | $5.12 | $178,365.44 |
DisclosureSEC source: 0000950170-24-080480 · ownership.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,000 F1 · kind: The sale reported on this Form 4 was effected pursuant to a trading plan adopted on March 29, 2024 pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 16:20 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0000950170-24-076262 · ownership.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:30 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0000950170-24-070705 · ownership.xml · derivative · entry 2 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2034-06-04 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 05, 2024 Filed Jun 7, 2024 20:30 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070705 · ownership.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,837 Read SEC document |
| September 16, 2023 Filed Sep 19, 2023 20:48 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionRestricted Stock Units · Derivative | 2,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049978 · doc4.xml · derivative · entry 2 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,334 Underlying: Common Stock · 2,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023. F3 · derivative.expiration_date: Represents a restricted stock unit award granted on September 16, 2022. These restricted stock units vest in three equal annual installments commencing on September 16, 2023. Read SEC document |
| September 16, 2023 Filed Sep 19, 2023 20:48 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | Exercise / conversionCommon Stock | 2,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-049978 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon vesting of a restricted stock unit award. F1 · price: Represents shares of common stock received upon vesting of a restricted stock unit award. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 16:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 18,118 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000899243-23-015153 · doc4.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,118 Underlying: Common Stock · 18,118 shares Expires 2033-06-06 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 02, 2023 Filed Jun 5, 2023 16:15 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | SaleCommon Stock | 5,000 | $8.00 | $40,000.00 |
DisclosureSEC source: 0000899243-23-014449 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 739,118 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:27 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $3.70 | $0.00 |
DisclosureSEC source: 0001209191-23-033738 · doc4.xml · derivative · entry 2 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires 2033-05-31 F2 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments of 8.33% of the shares underlying the award until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:27 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033738 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,171 F1 · balance_after: The amount of securities beneficially owned following the transaction reported in this Form 4 reflects the 1-for-10 reverse stock split effected by the issuer on September 16, 2022. Read SEC document |
| May 01, 2023 Filed May 3, 2023 16:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | SaleCommon Stock | 5,000 | $8.00 | $40,000.00 |
DisclosureSEC source: 0000899243-23-012077 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 744,118 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 16:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | SaleCommon Stock | 5,000 | $8.00 | $40,000.00 |
DisclosureSEC source: 0000899243-23-011034 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 749,118 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022. Read SEC document |
| March 17, 2023 Filed Mar 20, 2023 16:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | SaleCommon Stock | 10,000 | $8.00 | $80,000.00 |
DisclosureSEC source: 0000899243-23-009094 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 754,118 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 16:14 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | SaleCommon Stock | 20,000 | $8.00 | $160,000.00 |
DisclosureSEC source: 0000899243-23-001594 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 764,118 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022. Read SEC document |
| September 16, 2022 Filed Sep 19, 2022 21:16 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantRestricted Stock Units · Derivative | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-050562 · doc4.xml · derivative · entry 2 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Stock · 8,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: These RSUs will vest in three equal annual installments commencing on September 16, 2023. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022. F3 · derivative.expiration_date: These RSUs will vest in three equal annual installments commencing on September 16, 2023. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022. Read SEC document |
| September 16, 2022 Filed Sep 19, 2022 21:16 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001209191-22-050562 · doc4.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2032-09-15 F1 · derivative.exercise_date: The option becomes exercisable as to 16.66% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the third anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Amounts reported in this Form 4 reflect the 1-for-10 reverse stock split effected by the issuer on September 16, 2022. Read SEC document |
| September 14, 2022 Filed Sep 15, 2022 16:10 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | SaleCommon Stock | 10,000 | $8.00 | $80,000.00 |
DisclosureSEC source: 0000899243-22-031138 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 784,118 F1 · kind: The sales reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 16:10 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 18,118 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0000899243-22-021892 · doc4.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,118 Underlying: Common Stock · 18,118 shares Expires 2032-06-07 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 23:09 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $0.78 | $0.00 |
DisclosureSEC source: 0001209191-22-033714 · doc4.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2032-05-31 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 08, 2021 Filed Jun 10, 2021 21:31 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $6.30 | $0.00 |
DisclosureSEC source: 0001209191-21-039580 · doc4.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-07 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:34 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 3,750 | $12.05 | $45,187.50 |
DisclosureSEC source: 0001209191-21-011992 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 321,711 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.75 to $12.415, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 22:29 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 3,750 | $13.04 | $48,900.00 |
DisclosureSEC source: 0001209191-21-009341 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,461 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.69 to $13.30, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 21:33 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 5,357 | $8.75 | $46,873.75 |
DisclosureSEC source: 0001209191-20-059113 · doc4.xml · nonDerivative · entry 2 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,211 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| November 17, 2020 Filed Feb 10, 2021 22:28 UTC Amendment | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 5,357 | $8.75 | $46,873.75 |
DisclosureSEC source: 0001209191-21-009339 · doc4a.xml · nonDerivative · entry 2 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 329,211 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · balance_after: This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct a typographical error in Column 5 regarding the amount of securities beneficially owned by the reporting person following the reported transactions. Read SEC document |
| November 16, 2020 Filed Nov 18, 2020 21:33 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 633 | $8.98 | $5,684.34 |
DisclosureSEC source: 0001209191-20-059113 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,568 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.93 to $9.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 16, 2020 Filed Feb 10, 2021 22:28 UTC Amendment | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 633 | $8.98 | $5,684.34 |
DisclosureSEC source: 0001209191-21-009339 · doc4a.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 334,568 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.93 to $9.01, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F3 · balance_after: This amendment to the Statement of Changes in Beneficial Ownership of Securities is being filed to correct a typographical error in Column 5 regarding the amount of securities beneficially owned by the reporting person following the reported transactions. Read SEC document |
| October 19, 2020 Filed Oct 19, 2020 22:36 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 5,673 | $8.75 | $49,638.75 |
DisclosureSEC source: 0001209191-20-055334 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,201 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| October 15, 2020 Filed Oct 16, 2020 20:39 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 317 | $8.75 | $2,773.75 |
DisclosureSEC source: 0001209191-20-055059 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,874 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.75 to $8.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 15, 2020 Filed Sep 16, 2020 12:32 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 5,990 | $10.39 | $62,236.10 |
DisclosureSEC source: 0001209191-20-050618 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 341,191 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.03 to $10.63, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| August 17, 2020 Filed Aug 19, 2020 20:33 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 5,990 | $12.59 | $75,414.10 |
DisclosureSEC source: 0001209191-20-047501 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 347,181 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.90 to $12.99, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 20:11 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 5,990 | $11.85 | $70,981.50 |
DisclosureSEC source: 0001209191-20-042796 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,171 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.39 to $12.19, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 20:53 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 5,990 | $8.75 | $52,412.50 |
DisclosureSEC source: 0001209191-20-037001 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,161 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 11, 2020 Filed Jun 11, 2020 20:54 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $9.17 | $0.00 |
DisclosureSEC source: 0001209191-20-035971 · doc4.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| May 15, 2020 Filed May 15, 2020 21:13 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 5,990 | $9.22 | $55,242.18 |
DisclosureSEC source: 0001209191-20-029763 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,151 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.78 to $9.55, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 15, 2020 Filed Apr 17, 2020 20:02 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 23,960 | $8.75 | $209,650.00 |
DisclosureSEC source: 0001209191-20-024775 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,141 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 20:08 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 22,700 | $10.00 | $227,000.00 |
DisclosureSEC source: 0001209191-19-046516 · doc4.xml · nonDerivative · entry 2 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 395,101 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| August 15, 2019 Filed Aug 19, 2019 20:08 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 2,300 | $10.00 | $23,000.00 |
DisclosureSEC source: 0001209191-19-046516 · doc4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 417,801 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 20:18 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $5.60 | $0.00 |
DisclosureSEC source: 0001209191-19-036369 · doc4.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2029-06-10 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 20:30 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $12.95 | $0.00 |
DisclosureSEC source: 0001179110-18-008625 · edgar.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the date of grant, with the remainder vesting in equal monthly installments until the first anniversary of the date of grant, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 20:08 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 3,282 | $22.00 | $72,204.00 |
DisclosureSEC source: 0001104659-17-052251 · a4.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,101 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 25, 2017 Filed Jul 27, 2017 20:09 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | SaleCommon Stock | 3,282 | $22.09 | $72,495.77 |
DisclosureSEC source: 0001179110-17-010734 · edgar.xml · nonDerivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,383 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 08, 2017 Filed Jun 12, 2017 20:02 UTC | Syros Pharmaceuticals, Inc. SYRS · Entity 85437 | GrantStock Option (right to buy) · Derivative | 11,000 | $0.00 Strike: $14.26 | $0.00 |
DisclosureSEC source: 0001179110-17-008894 · edgar.xml · derivative · entry 1 Young Richard A · CIK 0001490283 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 11,000 shares Expires 2027-06-07 F1 · derivative.exercise_date: The option becomes exercisable as to 50% of the shares underlying the award on the six month anniversary of the award, with the remainder vesting in equal monthly installments until the first anniversary of the date of the award, subject to the reporting person's continued service as a director through each applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.